Halozyme stock down despite Q3 earnings and revenue beat
FROM THE WIRE · FINANCE.YAHOO.COM
Halozyme Therapeutics HALO reported third-quarter 2026 adjusted earnings of $2.39 per share, which beat the Zacks Consensus Estimate of $2.29. Earnings rose 39% year over year. Total revenues in the third quarter increased 39.2% year over year to $493 million. Revenues also…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralA quarterly beat matters for the stock, but the decline shows the market is looking beyond the headline.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Halozyme reported adjusted EPS of $2.39, versus a $2.29 consensus.
- 02Revenue rose 39.2% year over year to $493 million.
- 03Revenue beat the $482 million consensus estimate.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets